LITESPARK-012 Fails to Improve First-Line Outcomes in Advanced Renal-Cell Carcinoma
First-line treatment for advanced clear-cell renal-cell carcinoma remains anchored by pembrolizumab plus lenvatinib after a large randomized phase 3 test failed to show added benefit from either belzutifan or quavonlimab. In the open-label LITESPARK-012 study, both intensification strategies landed squarely beside the control regimen rather than ahead of it, despite strong biologic rationale for each approach.
The result is hard to ignore. Adding a HIF-2α inhibitor or an anti-CTLA-4 agent did not move progression-free survival or overall survival beyond the benchmark already set by pembrolizumab and lenvatinib.
Trial Design Tested Two Distinct Routes to Intensification
Adults with previously untreated advanced clear-cell disease were randomized in a 1:1:1 design. One arm received pembrolizumab 400 mg intravenously every 6 weeks, lenvatinib 20 mg orally daily, and belzutifan 120 mg orally daily. A second arm received the coformulated quavonlimab/pembrolizumab combination at 25 mg/400 mg intravenously every 6 weeks, together with lenvatinib. The control arm received standard pembrolizumab plus lenvatinib.
Treatment continued until progression, unacceptable toxicity, or withdrawal, and pembrolizumab or the quavonlimab/pembrolizumab combination could be given for a maximum of about 2 years. The study used dual primary endpoints of progression-free survival by blinded independent central review and overall survival. Arm A was compared with control across all randomized participants. Arm B was compared with control in participants with IMDC intermediate/poor risk or across all participants, depending on the endpoint framework.
The cohort was large enough to test the question without ambiguity. A total of 560 participants entered Arm A, 562 entered Arm B, and 566 entered the control arm. Median follow-up reached 43.6 months, with a range of 31.8 to 57.4 months.
Progression-Free Survival Stayed Flat Across All Three Arms
Among all participants, median PFS was 20.8 months with belzutifan, 20.7 months with quavonlimab, and 23.7 months in the control arm. The hazard ratios were 1.08 for Arm A versus control and 1.07 for Arm B versus control, with confidence intervals crossing 1 in both comparisons. P values were not persuasive: 0.8408 for Arm A and nominal 0.8174 for Arm B.
Those numbers matter because they suggest that intensifying immunotherapy or pairing checkpoint blockade with HIF-2α inhibition did not translate into earlier disease control. In a disease where angiogenesis, hypoxia signaling, and immune escape all fuel tumor persistence, the expectation was that stacking mechanisms might extend the interval before progression. Instead, median PFS remained essentially unchanged, and the control arm actually showed the numerically longer median at 23.7 months.
Survival Did Not Improve With Either Experimental Strategy
Overall survival told the same story. In Arm A, median OS was 52.0 months, with a hazard ratio of 1.04 versus control and a P value of 0.6622. In Arm B, median OS was not reached, but the hazard ratio was 1.12 versus control, with a nominal P value of 0.8955. Control arm OS was also not reached at the time of analysis.
Among participants with IMDC intermediate/poor risk, the quavonlimab strategy again failed to separate from standard treatment. Median PFS was 20.5 months in Arm B versus 23.5 months in the control arm, with a hazard ratio of 1.12 and P=0.8954. Median OS was 39.1 months versus 46.2 months, with a hazard ratio of 1.17 and P=0.9419.
The biology behind the negative readout is worth considering. Belzutifan targets tumor adaptation to hypoxia, while quavonlimab attempts to deepen T-cell activation through CTLA-4 blockade. Yet pembrolizumab plus lenvatinib already engages two powerful mechanisms: PD-1 release of immune inhibition and VEGF-pathway suppression through lenvatinib. Layering another checkpoint axis or hypoxia agent may have added toxicity without enough additional tumor control to change the endpoint curve.
Toxicity Rose Sharply When the Regimens Were Intensified
Safety shifted in the wrong direction. Any-grade all-cause adverse events led to any-drug discontinuation in 51.6% of participants in Arm A, 51.4% in Arm B, and 36.2% in the control arm. The excess discontinuation burden was not subtle, and it appeared in both investigational arms.
In clinical terms, this creates a familiar problem in front-line renal-cell carcinoma: when efficacy does not improve, every additional discontinuation becomes harder to justify. Lenvatinib already carries a toxicity profile that often requires careful dose management, and immunotherapy combinations can compound fatigue, hypertension, endocrine dysfunction, and other treatment-limiting effects. The intensified regimens did not buy a survival advantage, yet they did push more patients off therapy.
Standard Pembrolizumab Plus Lenvatinib Remains the Reference Point
The control arm’s performance was consistent with prior reports, and that consistency matters because it anchors the negative finding. The benchmark regimen delivered the expected efficacy and safety profile across a long follow-up period, which makes the failure of the experimental additions more meaningful rather than less. A weak control arm could have obscured a benefit; that did not happen here.
For oncologists treating previously untreated advanced clear-cell renal-cell carcinoma, the practical message is straightforward: neither belzutifan nor quavonlimab improved outcomes when added to pembrolizumab plus lenvatinib in this phase 3 setting. Both investigational strategies also increased discontinuations due to adverse events.
The study leaves open a narrower question about whether either agent could still find a role in a different sequence, a different biomarker-defined subgroup, or a different backbone. No such signal emerged here, and the current randomized data do not support routine first-line intensification beyond pembrolizumab plus lenvatinib.